Introduction
Pancreatic ductal adenocarcinoma is a common disease and a leading cause of cancer-related deaths in the Western world.
1,2 Around 80% of patients have locally advanced or metastatic disease at the time of presentation. For these patients, the median survival is 6-9 months and treatments, including chemotherapy or chemotherapy combined with radiotherapy, have very limited benefit in terms of prolonging life. Most recently, combining gemcitabine, the standard of care for advanced disease, with other agents has begun to show promise, 3, 4 increasing the 1-year survival to around 25%. Patients who undergo surgery have a better prognosis, with chemotherapy in this setting demonstrated to prolong survival. 5 Nonetheless, the overall 5-year survival for patients with pancreatic ductal adenocarcinoma is less than 5% 6 and new treatments must therefore be explored. Given our improved understanding of the genetic basis of pancreatic cancer combined with advances in molecular engineering, gene therapy provides a promising adjunct to current therapeutic regimes. With respect to gene therapy approaches for pancreatic cancer, a variety of gene delivery methods as well as intracellular targets have been explored. [7] [8] [9] Our own experience has been with adenoviral vectors, which showed efficient gene delivery to pancreatic cancer cells. 10, 11 However, for this vector type to be used in humans, barriers such as pre-existing immunity and shortlived expression need to be overcome. 12 Moreover, the risk of toxicity to the pancreas, in the form of pancreatitis, 13 is a particular concern when targeting this organ. Alternative viral vectors such as those based on oncoretroviruses have shown promise, both in animal models of pancreatic cancer, for example in Stapfer et al.
14 and Ziske et al. 15 and in humans. 16 However, low viral titers and an inability to deliver genes to nonactively growing cells present significant limitations. Lentivectors, on the other hand, can be produced to relatively high titers and can transduce both dividing and nondividing cells, optimizing the possibility for maximum transduction within the tumor. 17 The potential for lentivector-mediated gene delivery to pancreatic cancer cells has not been systematically explored. Since their development almost a decade ago, 18 these vectors have undergone several successful modifications aimed at reducing pathogenicity and improving transfer gene expression. 19 Early vector designs were based on the human immunodeficiency type-1 virus (HIV-1); however, vectors based on feline, simian and equine lentiviruses have also been developed [20] [21] [22] [23] and address the potential difficulties faced by the introduction into clinical use of vectors derived from HIV-1, a serious human pathogen. Lentivectors have a wide host range, 19 and several recent studies establish a role for them in cancer research and treatment. [24] [25] [26] They offer a number of distinct advantages including a large insert capacity (8-9 kb), lack of expression of immunogenic viral components, and as integrative vectors, they have the potential to lead to stable and long-term expression of the transgene.
In this study, we demonstrate gene delivery to pancreatic cancer cells with both primate, HIV-1-based and nonprimate, equine infectious anemia virus (EIAV)-based lentivectors. Further, using pancreatic cancer cell lines, we have also employed primary pancreatic human cancer tissue xenografted into nude (nu/nu) mice. We consider the latter to be particularly important since they are derived from human cancer specimens transplanted into nu/nu mice, 27 and are likely to be more representative of the original features of human pancreatic cancer than cell lines kept in vitro for many passages.
Materials and methods

Cell lines and cell culture
All the cell lines used in this study were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The human embryonic kidney (HEK) 293T cell line, used for production of all vectors and titration of enhanced green fluorescent protein (EGFP)-vectors, was maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, Dorset, UK) while the human pancreatic cancer cell lines Panc-1, Suit-2, MiaPaCa-2, BxPc-3 and CFPac-1, used in transduction experiments were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich). All media were supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all reagents from Sigma-Aldrich). Cell lines were grown in a humidified incubator at 371C in 5% CO 2 , and were free of mycoplasma contamination.
Lentivector constructs
The constructs used for the production of both the HIV and EIAV vector systems were kindly provided by Oxford BioMedica and have been previously described. Briefly, the HIV-based vectors were generated using four lentiviral constructs, a gag/pol packaging construct pCIHIVsyngp, 28 a genome transfer construct (pHF1G) carrying the EGFP transgene and containing a central polypurine tract (cPPT) element ( Figure 1a ) 29 and expression plasmids carrying VSV-G envelope genes (pRSV67) 30 and rev genes (pHRev REF), respectively. In the case of the EIAV-based vectors, the system included three constructs; a gag/pol packaging construct (pONY3.1), 31 a vector plasmid encoding EGFP (Figure 1b ; pO-NY8.0G) 32 and a VSV-G encoding plasmid (pRSV67, as above). For the expression of the actin-capping protein CapG, the CapG gene was cloned, as described below, into pONY8.7NCmcs, which contains a cPPT element, the woodchuck post-transcriptional regulatory element (WPRE) and a neomycin resistance gene (Figure 1c) .
The cDNA sequence for CapG was generated following mRNA isolation from Suit-2 cells and cloned into the expression vector (pGEM-T Easy, Promega, Southampton, UK). The sequence was then amplified by PCR using primers (5 0 -CCGCTCGAGACAGCATGTACACAGCC ATTC-3 0 and 5 0 -ACGCGGTGATCACACCCTCATTT CCAGTCC-3 0 ), which contained XhoI and BclII restriction sites, respectively, and HotStart Taq polymerase at the following conditions: 951C for 15 min followed by 37 cycles of PCR (941C for 30 s, 601C for 1 min and 721C for 2 min) and a final extension at 721C for 10 min. The amplicon was then digested with XhoI and BclII and cloned into XhoI and BclII restriction sites of pO-NY8.7NCmcs. The resulting recombinant vector construct, as well as a control lacking the CapG transgene was used to produce EIAV vectors. The new vectors were termed LV-CapG ( Figure 1c ) and LV-control, respectively. and 48 h after transfection, subjected to low-speed centrifugation at 6000 g for 5 min at room temperature (RT) and then filtered through 0.45 mm pore-size filters. Vector preparations were concentrated 1200-fold by ultracentrifugation at 50 000 g for 2 h at 41C. Vector pellets were resuspended in physiological balanced solution (PBS) containing 0.5% bovine serum albumin (BSA) (Sigma-Aldrich) and frozen at À801C until use.
Lentivector production
Transduction of cells in culture
Titers (transducing units (TU)/ml) of EGFP-expressing lentiviral vectors were determined by transducing 0.5 Â 10 5 HEK 293T cells/well seeded in six-well plates in duplicate with serial dilutions of vector. Medium was changed 3 h before transduction. Transductions were performed in a total volume of 600 ml of vector-containing medium, supplemented with polybrene (8 mg/ml). After 3 h, the volume of medium was increased to 3 ml and cells were incubated for a further 48 h. Cells were then fixed using PBS containing 1% formaldehyde and 2% BSA. The percentage of EGFP-positive cells was determined by fluorescence-activated cell-sorting (FACS) analysis performed on 10 000 fixed cells per sample, using a FACScan cytometer (Becton-Dickinson UK Ltd, Oxford, UK). Results were analyzed using WinMDI (version 2.8) software (Scripps Institute). Lentiviral vectors stocks produced as described above typically contained 10 8 TU/ml. Pancreatic cancer cells were transduced in six-well plates, with specified multiplicities of infection (MOIs) ranging from 1 to 10 as described above.
Quantitative analysis of lentivector stocks by viral RNA assays Viral RNA assays were performed essentially as described by Martin-Rendon et al. 33 Briefly, to isolate viral vector genomic RNA, a predetermined titer of HIV and EIAV vector (3 Â 10 6 TU) was diluted to 20 ml in PBS and RNA isolated using a QIAamp viral RNA extraction mini kit (Qiagen, Crawley, UK). The extracted RNA was eluted in a final volume of 60 ml, aliquoted and stored at À801C. To remove DNA, eluted RNA was DNase treated (RNaseFree DNase Set; Qiagen) at 371C for 30 min. Isolated viral RNA (10 ml) and dilutions of this (10 ml of 10-fold serial dilutions) were subjected to RT using the RT SS II (Invitrogen Ltd, Paisley, UK) and the reverse primer 5 0 -GACTGGGTGCTCAGGTAGTGG-3 0 for 30 min at 421C in a final volume of 20 ml. From the resulting cDNA, a region of 300 bp corresponding to the sequence of EGFP was then specifically amplified using LightCycler technology. In brief, 1 ml of each RT reaction mix was incubated with a FastStart SYBR green I reaction mix (Roche, Welwyn, UK), 1.5 mM Mg 2 þ , the reverse primer as above and the forward primer 5 0 -GCAACTA CAAGACCCGCGCCG-3 0 , and subjected to initial denaturation at 951C for 10 min followed by 50 cycles of PCR (941C for 10 min, 551C for 5 s and 721C for 30 s). For each vector stock under analysis, RNA was isolated and processed on three independent occasions. The threshold (C t ) value is the cycle at which there is a significant increase in the signal generated (and reflects the amount of template or target). C t values for diluted HIV and EIAV stocks were compared. Paired t-tests were performed to examine for statistical differences. Statistical calculations were undertaken using StatView version 5.01 software (SAS Institute Inc., Marlow, UK). Results were considered significant for P-valueso0.05.
Lentiviral vector-mediated delivery of CapG and selection of positively transduced cells Pancreatic cancer cell lines Panc-1, MiaPaCa-2 and Suit-2 were transduced with EIAV-vector carrying both the CapG gene and a neomycin resistance gene (LV-CapG) or the neomycin resistance gene only (LV-control) in 10-cmdiameter plates, in a total volume of 1 ml of medium supplemented with polybrene (8 mg/ml). After 3 h, the volume of medium was increased to 5 ml and incubation continued. Transduced cells were incubated with G418 at predetermined optimal concentrations of 400 mg/ml for Panc-1 and MiaPaCa-2 and 600 mg/ml for Suit-2 and selected over a period of 10 days. Clones were derived from Panc-1 cells. These and nonclonal G418-resistant populations from all cell lines were analyzed for the detection of CapG by western blot as described below.
Western blot analysis
Cells were harvested and incubated in a lysis buffer containing 50 mM HEPES, pH 7.5, 10% glycerol, 0.1% Triton X-100, 150 mM NaCl, 1 mM PMSF, 1 mM DTT, 0.5 mg/ml and the protein inhibitors, 0.5 mg/ml leupeptin, 0.25 mg/ml aprotinin and 0.5 mg/ml pepstatin, for 10 min on ice. Samples were processed by centrifugation (13 000 r.p.m., 10 min) and protein quantity was evaluated by the Bradford method (BioRad, Hemel Hempstead, UK). Aliquots containing 5-10 mg of protein were subjected to electrophoresis on 10% SDS-PAGE gels and electroblotted onto nitrocellulose membranes (Amersham Life Science, Buckinghamshire, UK). Membranes were blocked in Tris-buffered saline (TBS) containing 0.1% Tween-20 with 5% nonfat powdered milk, for 1 h at room temperature and then incubated with the primary rabbit anti-CapG antibody (kindly provided by Dr H Yin, University of Texas Southwestern Medical Centre, Dallas, TX) in TBS containing 0.1% Tween-20 with 5% BSA and washed three times in TBS containing 0.1% Tween-20. Detection was based on a secondary anti-rabbit HRP-conjugated antibody (DAKO) and electrochemiluminescence, using Western Lighting Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Beaconsfield, UK). Blots were stripped in erasure buffer (2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.8, 100 mM b-mercaptoethanol) for 1 h at 701C, and reprobed with GAPDH (Sigma-Aldrich). SeeBlue Plus2 pre-stained standard (Invitrogen) was used as a molecular protein marker. These analyses were performed regularly over a period of 6 months to monitor the expression of the CapG transgene in human pancreatic cancer cell lines. These vectors thus provide a useful method to obtain variable levels of gene expression in pancreatic cancer cells in a stable fashion that can be maintained over extended periods of time.
In vivo gene transfer studies MiaPaCa2 cells were suspended in complete medium at 2.5 Â 10 6 cells/ml and then mixed with cold Matrigel in a 1:1 volume ratio. An aliquot of this suspension (0.4 ml) was inoculated subcutaneously in the flank of 4-week-old nu/nu Swiss mice weighing 18-22 g (Charles River, Milan, Italy). Xenografts of primary pancreatic human cancer tissue fragments were prepared as described previously 27 and with full ethical approval. Cancer tissue originated from five patients, three of which were diagnosed with pancreatic cancer of the head while two were diagnosed with pancreatic cancer of the body. Tumor formation was checked weekly by visual inspection and gauge measuring. When tumors reached at least 1 cm in diameter, after approximately 4 weeks of incubation, the xenografts were injected with 100 ml of each lentiviral vector (2.0 Â 10 7 TU) in PBS, using a digital pump (SP100i Syringe Pump, WPI, Sarasota, FL, USA), at a flow rate of 1.5 ml/h. The mice were incubated with each lentiviral vector for 48 h and subsequently killed. Tissue was then removed, fixed in formalin solution for 24 h, incubated in paraffin and sectioned. For MiaPaCa2 xenografts, the occurrence of transduction in situ was visualized by detection of EGFP using an Alexa-Fluor 488-labeled anti-GFP antibody (Molecular Probes, Eugene, OR, USA), while ethidium bromide (EtBr) was used for staining nuclei. To quantify precisely the transduction efficiency in xenografted human tumors, they were subjected to collagenase digestion, fixation in 10% cold formalin in PBS and permeabilization with 0. 
Results
Characterization of lentivector preparations
Before performing experiments on pancreatic cancer cell lines, the titers of EGFP-expressing vector stocks were assessed using 293T cells. This provided a measure of the ability of the respective vectors to achieve gene expression in these cells. Since titers are cell-type-specific, we also assessed the content of viral RNA in these vector stocks, which provides an estimation of the potential of the vectors to transduce target cells in general. Three independent EIAV and three HIV vector stocks were analyzed. In each case, RNA was extracted from 3 Â 10 6 TU, and 10-fold serial dilutions were subjected to real-time RT-PCR, performed in triplicate at each dilution. We found that for the same biological titers on 293T cells, HIV and EIAV vectors contained similar quantities of viral RNA (Figure 2 EIAV vector-mediated gene delivery to pancreatic cancer results in stable and long-term expression of the transgene Pancreatic cancer cells are relatively refractory to transfection using either chemical-or lipid-based methods. Thus, effective tools to facilitate gene delivery to these cells in a research setting are welcome. In this study, a mutant form of CapG, an actin-capping protein, whose expression and function appear to be particularly important in pancreatic cancer cells 34 was cloned into an advanced EIAV transfer vector that enabled selection using G418. Control cells were transduced with an identical EIAV vector containing the NeoR cassette only. Long-term overexpression of the transgene was investigated in Panc-1, Suit-2 and MiaPaCa-2 cells. Examples of Panc-1-derived cell clones are shown in Figure 5a . In addition, nonclonal G418-resistant populations from each cell line were also retained and CapG expression monitored at intervals for up to 6 months. Using this system, we found that cells expressing CapG to different levels could be obtained (Figure 5b ) and also that overexpression was maintained for up to 6 months (Figure 5c ), when the experiment was stopped.
Lentiviral vector-mediated delivery of EGFP to human pancreatic cancer in vivo
Before attempting lentiviral-mediated gene delivery to xenografts of human primary pancreatic cancer tissue in mice, we first examined the transduction of MiaPaCa-2 xenografts. About 2.0 Â 10 7 TU of HIV-or EIAV-based vectors harboring the EGFP gene as before resulted in EGFP expression, as detected by immunofluorescence of paraffin sections of MiaPaCa-2 tumors (Figure 6a) . Xenografts of human primary pancreatic cancer tissue were similarly innoculated with 2.0 Â 10 7 TU of vector (see Materials and methods). Xenografts from a total of five patients (P1-P5) were used and in two cases (P1 and P2), separate xenografts from the same patients were innoculated with both vector types. In the remaining three cases, two were inoculated with EIAV-EGFP (P3 and P4) and the third with HIV-EGFP (P5). FACS profiles are shown in Figure 6b , while Figure 6c shows the volume of each tumor xenograft and the percentages of cells that were positive for EGFP expression at 48 h post transduction. We observed that both vectors resulted in gene delivery to primary tumor xenografts. Although all tumors were innoculated with the same viral titer, the percentage of cells transduced varied, ranging from 3 to 30%. In the cases of P1, the HIV-based vector resulted in greater transduction; however for P2, this was true of the EIAV-based vector. As the xenografts were derived from tissue fragments (the neoplastic cells did not survive in vitro in standard culture medium), we could not synchronize the growth of the tumor mass. However, while it is likely that the efficiency of transduction was affected by tumor size, a direct relationship between tumor volume and the percentage of cells transduced was not apparent.
Discussion
Pancreatic cancer is largely refractory to current therapeutic approaches and carries a very poor prognosis. 35 As such, it is an appropriate target for the development of new therapies. Enhanced understanding of the molecular basis of pancreatic cancer 36 has provided a wide range of potential intracellular targets for gene therapy approaches. These have included the replacement of tumor suppressor genes (TP53, CDKN2A), the inactivation of oncogenes (KRAS) and targeting of apoptotic and angiogenic pathways. 7 However, finding efficient gene delivery tools remains an enormous challenge. In this study, we set out to assess the potential of lentivectors for gene delivery to pancreatic cancer cells. These vectors offer a unique combination of features that make them attractive as gene delivery tools, such as their ability to confer efficient, stable and long-term gene expression in both dividing and nondividing cells. 19 However, this particular feature comes with a distinct caveat; the potential to induce insertional mutagenesis. While this is a grave concern, it has to be rationalized in the context of each target disease and in the case of pancreatic cancer, the median survival for patients with advanced disease continues to be less than 6 to 8 months. 6 Lentivectors have been successfully used to transfer genes in a large range of cell types including benign cellular components of the pancreas. [37] [38] [39] [40] Their application for gene delivery to tumor cells is increasingly being examined and in this context they have fared very well when compared to other vector types. 41, 42 Vectors developed using EIAV provide an alternative to HIV-based vectors. EIAV does not cause a lethal disease in its own natural host, the genus Equidiae, where disease severity decreases over time. Moreover, EIAV cannot replicate in human cells. Vectors based on EIAV may therefore be more readily adopted, than HIV-based vectors, for clinical use in humans.
We found that both HIV-and EIAV-based vectors can be used to transduce pancreatic cancer cells. We evaluated the performance of both vectors in five pancreatic cancer cell lines. In all cases, transduction was observed, although some cell lines, particularly MiaPaCa-2 and Panc-1 were more receptive to transduction by both vectors while others, for example CFPac-1 were less readily transduced by both vectors. The reasons underlying the differences in the transduction efficiencies observed in different cell lines are not clear, although they may reflect differences in viral entry, immediate early cytomegalovirus (CMV) promoter activity or the genotype of individual cancer cell lines. We also observed differences in the level of transduction between HIV-and EIAV-based vectors. When used at similar MOIs, we consistently observed greater levels of transduction with HIV-EGFP in each cell line examined. There was no evidence to suggest that a given titer of EIAV-EGFP, as assessed on 293T cells, had less potential to transduce pancreatic cancer cells, since both EIAV-EGFP and HIV-EGFP vectors contained similar quantities of RNA, implying similar numbers of particles. However, the HIV-EGFP vectors carried an important cis-acting element, the cPPT element, that was absent from the EIAV-EGFP vectors. This element promotes nuclear import of the HIV genome 43 and is known to increase the transduction efficiency of viral vectors. 44 Such regulating elements are not exclusive to a particular lentiviral vector type. Later generations of EIAV vectors including the one employed for the delivery of CapG to pancreatic cancer cells in this study have included similar features to ensure higher transduction efficiencies.
Our study additionally examined lentiviral vectormediated delivery to both MiaPaCa-2 cells and human primary pancreatic xenografts implanted subcutaneously in nude mice. Transduction of MiaPaCa-2 xenografts was readily observed with both vectors. However, our observation of successful transduction of human primary pancreatic xenografts provides, we believe, the best indication that human pancreatic tumors may be a suitable target for gene delivery protocols using lentiviral vectors. These xenografts are derived from primary cancer specimens 27 and, unlike established cell lines, have not had the opportunity to acquire mutations or adapt to their environment during numerous culture passages. As with the cell lines, variation in transduction efficiency of xenografts was observed. While this may relate to the variation in tumor sizes, it may also reflect differences in the biology of distinct tumors. A study involving considerably larger numbers of xenografts would be required to relate the genetic characteristics of the primary tumors used to levels of transduction achieved.
Lentivectors have now become a well-established research laboratory tool. We observed that lentivectormediated delivery in pancreatic cancer cell lines resulted in stable and long-term expression of the CapG transgene. We report the role of this protein in pancreatic cancer elsewhere. 34 However, in this study, detection of CapG overexpression served to demonstrate that lentiviral vector-mediated gene delivery to pancreatic cancer can yield stable transgene expression over a period of at least 6 months. These findings are supported by reports on the persistence of transgene expression in lung and breast cancer cells. 45 Finally, while this work was in progress, two reports of lentiviral vector-mediated transduction of pancreatic cancer cell lines emerged. 26, 46 Our data are consistent with these studies, both of which showed successful transduction of pancreatic cancer cells with a HIV-based vector. To our knowledge, there are no previous reports of EIAV-mediated gene transfer to pancreatic cancer cells and ours is also the first report of lentiviral-mediated gene delivery to human primary xenografts in mice.
In summary, we show that pancreatic cancer cells are suitable targets of both EIAV-and HIV-based lentiviral vector-mediated gene delivery. These vectors are useful laboratory research tools and have potential as mediators of clinical gene therapy for pancreatic cancer in future. The differences in transduction efficiencies between individual cell lines and primary xenografts will require further exploration, particularly if these vectors are to be applied in a clinical setting.
